# Proof of concept for high-dose Cannabidiol pretreatment to antagonize opioid induced persistent apnea in mice

**Authors:** Beth M. Wiese, Evgeny Bondarenko, Jack L. Feldman

PMC · DOI: 10.3389/fnins.2025.1654787 · Frontiers in Neuroscience · 2025-10-08

## TL;DR

CBD pretreatment may prevent opioid-induced breathing problems in mice as effectively as naloxone, with potential to enhance life-saving treatments.

## Contribution

CBD pretreatment is shown to prevent opioid-induced respiratory depression and increase fentanyl LD50 in mice.

## Key findings

- CBD is as effective as naloxone in preventing opioid-induced respiratory depression in awake mice.
- CBD increases the median lethal dose of fentanyl in anesthetized mice.
- CBD combined with naloxone increases fentanyl LD50 more than either alone.

## Abstract

Opioid related fatalities remain a public health crisis in the US. Currently, the only way to restore breathing following an opioid induced persistent apnea is with the administration of the opioid antagonist naloxone, but it also reverses analgesia, euphoria, and induces precipitated withdrawal in opioid dependent individuals.

Using whole-body plethysmography, we assessed changes in breathing frequency in awake behaving mice resulting from a single fentanyl dose (50 mg/kg i.p.) that followed i.p. pretreatment with saline, vehicle, naloxone (100 mg/kg), cannabidiol (CBD) (250 mg/kg), or CBD + naloxone. Then we assessed the delay to opioid-induced persistent apnea (OIPA) and the median lethal dose (LD50) of fentanyl during a continuous i.c.v. infusion of fentanyl (100 ng/min), in urethane anesthetized mice, following pretreatment with saline, vehicle, naloxone (100 mg/kg), CBD (250 mg/kg), or CBD + naloxone i.p.

Here we show acute pretreatment with CBD is as effective as naloxone at preventing opioid-induced respiratory depression from fentanyl in awake mice, and increasing LD50 of fentanyl in urethane anesthetized mice. When pre-administered together, CBD + naloxone, increased LD50 of fentanyl even more than CBD or naloxone alone in urethane anesthetized mice.

CBD may be an effective preventative therapy for OIPA by increasing the time before apnea onset and potentially enhancing the efficacy of naloxone as an additional strategy to save lives.

## Linked entities

- **Chemicals:** Cannabidiol (PubChem CID 644019), fentanyl (PubChem CID 3345), naloxone (PubChem CID 4425), urethane (PubChem CID 5641)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Diseases:** OIPA (MESH:D000079689), respiratory depression (MESH:D012131), apnea (MESH:D001049), analgesia (MESH:D000699)
- **Chemicals:** naloxone (MESH:D009270), fentanyl (MESH:D005283), CBD (MESH:D002185), urethane (MESH:D014520)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12540426/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12540426/full.md

## References

40 references — full list in the complete paper: https://tomesphere.com/paper/PMC12540426/full.md

---
Source: https://tomesphere.com/paper/PMC12540426